Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · 行业原文收录 · 来源发布：Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chai
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。